ALKBH2 promotes the Warburg effect and bladder cancer progression under hypoxic conditions via the PI3K/AKT pathway Authors: Zhangjie Yang, Jinhu Ma, Ziyang Qiang, Wenhao Xie, Liang Jiao, Zhenxing Hu, Tiange Zhang, Limei Zhang, Jinqiong Lv, Fangqian Yue, Guojun Chen Published: 2026 ABSTRACT Emerging evidence links DNA repair enzymes to metabolic reprogramming in cancer. ALKBH2 safeguards genomic integrity by reversing alkylation damage, yet its potential role beyond repair—specifically in modulating the Warburg effect—remains unexplored in bladder cancer. While implicated in digestive tract malignancies, ALKBH2’s function in urothelial carcinoma is unknown. Investigating this gap may reveal ALKBH2 as a novel metabolic driver in bladder cancer progression. ALKBH2 expression was analyzed in bladder cancer tissues and matched adjacent normal tissues by qPCR, Western blotting, and immunofluorescence (IF). Hematoxylin and eosin (H&E) staining was used to confirm tissue histology. Using stable ALKBH2-overexpressing and knockdown bladder cancer cell lines, we systematically assessed the effects of ALKBH2 on tumor cell behavior in vitro and tumor growth in vivo. Moreover, its involvement in hypoxia-associated Warburg metabolic reprogramming was investigated under 1% O₂. In vitro, ALKBH2 overexpression enhanced bladder cancer cell proliferation, migration, invasion, and clonogenicity, whereas ALKBH2 knockdown exerted opposite effects. Consistently, in vivo xenograft models demonstrated that silencing ALKBH2 significantly suppressed tumor growth. Mechanistic investigations revealed that ALKBH2 functions as an m6A demethylase to reduce PTEN mRNA stability, thereby activates the PI3K/AKT signaling pathway under hypoxic conditions, as evidenced by increased pathway activation, thereby facilitating metabolic reprogramming and tumor cell progression. These findings suggest that ALKBH2 plays a critical oncogenic role in bladder cancer by regulating PI3K/AKT pathway activation and promoting the Warburg effect, highlighting its potential as a therapeutic target for bladder cancer.Supplementary InformationThe online version contains supplementary material available at 10.1007/s10238-026-02212-5. Introduction Bladder cancer is the most common malignancy of the urinary system and ranks among the top ten most prevalent cancers in China, with both incidence and mortality showing a steady increase in recent years [1, 2]. Urothelial carcinoma represents the predominant histological subtype, whereas squamous cell carcinoma and adenocarcinoma are relatively rare [2, 3]. Clinically, bladder cancer is classified into non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) based on the depth of tumor infiltration [3]. Although NMIBC accounts for approximately 75% of newly diagnosed cases, it is characterized by a high recurrence rate, while MIBC, representing about 25% of cases, is associated with aggressive behavior and poor prognosis [3, 4]. Despite advances in surgical, intravesical, and systemic therapies, the prognosis of advanced bladder cancer remains unsatisfactory, highlighting the urgent need to identify novel mechanisms and therapeutic targets [2, 5]. Beyond genetic alterations, bladder cancer is increasingly recognized as a metabolic disease. In particular, the hypoxic tumor microenvironment profoundly reshapes cellular energy metabolism, favoring aerobic glycolysis (the Warburg effect) as a dominant metabolic strategy supporting tumor cell survival, rapid proliferation, and malignant progression [6–8]. Accumulating evidence indicates that enhanced glycolytic flux and lactate production enable tumor cells to adapt to metabolic stress, sustain biosynthetic demands, and promote invasive behavior [9–11]. However, the upstream molecular regulators that couple hypoxia to metabolic reprogramming in bladder cancer remain incompletely understood. Alkylation repair homolog 2 (ALKBH2) is a member of the AlkB family of Fe²⁺/α-ketoglutarate–dependent dioxygenases, which primarily function in the direct reversal of alkylated DNA lesions [12, 13]. Early studies demonstrated that AlkB deficiency leads to hypersensitivity to alkylating agents, underscoring its critical role in maintaining genomic integrity [14]. In humans, the AlkB family comprises nine homologs (AlkBH1–8 and FTO), several of which have been implicated in cancer development and progression [15]. Increasing evidence suggests that aberrant ALKBH2 expression is associated with tumorigenesis and therapeutic response in multiple cancers. For example, ALKBH2 has been reported to modulate chemotherapy sensitivity in non–small cell lung cancer and to influence tumor growth and prognosis in digestive system malignancies such as colorectal and gastric cancer [16–18]. In bladder cancer, however, evidence remains limited. To date, only one study by Fujii et al. has reported that ALKBH2 contributes to bladder cancer progression by regulating MUC1 expression, while the broader biological functions and mechanistic basis remain unclear [19]. Notably, recent studies have revealed a close interplay between DNA damage repair pathways and cellular metabolic reprogramming [20]. Moreover, other AlkB family members, such as FTO and ALKBH5, have been shown to regulate cancer metabolism through RNA modification–dependent mechanisms [21]. These findings raise the possibility that ALKBH2 may exert noncanonical functions beyond DNA repair. Whether ALKBH2 participates in metabolic reprogramming—particularly in the regulation of the Warburg effect under hypoxic conditions in bladder cancer—has not yet been explored. In the present study, we aimed to investigate the role of ALKBH2 in hypoxia-driven metabolic reprogramming and bladder cancer progression. We demonstrate that ALKBH2 promotes bladder cancer cell proliferation, migration, invasion, and tumor growth. Mechanistically, we reveal that ALKBH2 functions as an m6A demethylase targeting PTEN mRNA, thereby activates the PI3K/AKT signaling pathway, a central regulator of glucose metabolism and cell survival, thereby enhancing glycolytic activity and reinforcing the Warburg effect. Collectively, our findings uncover a previously unrecognized metabolic function of ALKBH2, linking its demethylase activity to hypoxia-associated glycolysis, and identify ALKBH2 as a potential metabolic therapeutic target in bladder cancer. Methods Patient samples and ethics statement A total of 58 paired tumor and adjacent nontumorous tissue (> 1 cm) samples were obtained from bladder cancer patients undergoing transurethral bladder tumor resection or radical cystectomy at the Affiliated Hospital of Qinghai University. All surgical samples were confirmed to be urothelial carcinoma by a pathologist. The use of all human tissue samples was approved by the Ethics Committee of the Affiliated Hospital of Qinghai University (Study identifier P-SL-2023-463). Four-week-old male BALB/c nude mice were purchased from the Shanghai SLAC Laboratory Animal Co., Ltd, were fed in a specific pathogen-free (SPF) level laboratory (temperature: 20–26 C; relative humidity: 40–50%). The experiments were approved by the Institutional Animal Care and Use Committee of the Affiliated Hospital Qinghai University (Study identifier P-SL-2023-463). Cell lines and culture conditions UMUC-3, TCCSUP and T24 cell lines (Cell Bank of the Chinese Academy of Sciences, Shanghai, China), authenticated by STR profiling. UMUC-3 and TCCSUP were cultured in MEM, while T24 was cultured in 1640, supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin, under 95% humidity and 5% CO2 at 37 °C. For hypoxia experiments, cells were cultured in 1% O2 with a Thermo Scientific™ Forma 3 incubator. Gene transfection and knockdown Lentiviral particles expressing ALKBH2 overexpression or shRNA constructs (GenePharma, China) were used to generate stable cell lines. The target sequences are listed in Table S1. Cells (3–5 × 105) were seeded in 6-well plates to achieve 60–70% confluency and transduced with lentivirus at a dilution of 1:10 (titer: 2 × 108 TU/mL). After 6 h, the culture medium was replaced. Transfection efficiency was assessed after 48 h by fluorescence microscopy, calculating the percentage of GFP-positive cells. Cell-based functional assays (CCK-8, colony formation, migration and would healing) Cells were seeded in 96-well plates at a density of 1,000 cells/well. Following treatment, 10 µL of CCK-8 solution (Meilunbio, Dalian, China) was added to each well containing 100 µL of medium. Absorbance was measured at 450 nm using a microplate reader (Thermo Scientific, Waltham, MA, USA). Each experiment was performed in triplicate and repeated independently three times. Cells (2 × 10³ per well) were seeded into 6-well plates and cultured for 7 days to allow colony formation. Visible colonies were fixed with 95% ethanol for 30 min, stained with 1% crystal violet for 15 min, and then photographed and counted. For the cell migration experiment, 3 × 104 cells were seeded in the upper chamber of a Transwell plate (Corning, USA), and 500 µL of culture medium supplemented with 20% FBS was added to the lower chamber as a chemotactic agent. To assess cell invasion, Matrigel (BD, USA) was added to the Transwell chamber before the cells were seeded. The cells were incubated at 37 °C for 24 or 48 h, the cells in the upper chamber were removed, and then, the cells that had migrated or invaded were fixed with 4% paraformaldehyde. The fixed cells were stained with crystal violet. The data were analyzed using ImageJ software (NIH, USA). Cells (9 × 105) were plated in 6-well plates and grown to 100% confluence. A linear wound was created by scratching the monolayer with a 10 µL pipette tip. Cells were cultured medium without FBS at 37 °C in 5% CO2, and images were captured after 36 h. Cell proliferation and apoptosis The proportion of fluorescent cells was determined by flow cytometry. Cells were fixed in 70% ethanol, stained with propidium iodide (PI) and RNase A, and analyzed by flow cytometry to determine the proportion of cells in G0/G1, S, and G2/M phases based on DNA content by cell cycle kit (Beyotime, Shanghai China). Cell apoptosis was conducted by cell apoptosis kit (Beyotime, Shanghai China). Cells were stained with PI and Annexin V-PE and analyzed by flow cytometry within 1 h to distinguish viable (Annexin V⁻/PI⁻), early apoptotic (Annexin V⁺/PI⁻), late apoptotic (Annexin V⁺/PI⁺), and necrotic (Annexin V⁻/PI⁺) populations. Histological analysis Bladder tissue was fixed in 4% paraformaldehyde for 12 h and sectioned at 5 μm thickness. Haematoxylin and eosin (H&E) staining was performed: Slides were deparaffinized and stained with haematoxylin for 1 min before soaking in eosin for 5 s. Images were captured using a microscope (Leica, DM500, Solms, Germany). Immunofluorescence (IF) After deparaffinization, sections were permeabilized with 0.5% Triton X-100 for 20 min and blocked with goat serum for 1 h at room temperature. Sections were then incubated with primary antibody (ALKBH2, PI3K, AKT, 1:200) overnight at 4 °C, followed by fluorescein- or rhodamine-conjugated goat anti-mouse/rabbit IgG for 1 h. Tissues were counterstained with DAPI for 5 min before observation under a microscope (TissueGnostics, Austria). Details about the antibodies used are provided in Table S2. Molecular assays (qPCR, Western blot) Total RNA was extracted from cells using a GeneJET RNA Purification Kit (Thermo Fisher Scientific, Waltham, MA, USA) and was used for cDNA synthesis with a Goldenstar RT6 cDNA Synthesis Kit (Tsingke Biotechnology). q-PCR was performed using Master q-PCR Mix (Tsingke Biotechnology) and a CFX96 Touch q-PCR Detection System (Bio-Rad). The primers were synthesized by Tsingke Biotechnology, and Actin was used as an internal control. The 2−ΔΔCT method was used to calculate relative gene expression. The primer sequences are listed in Table S1. Tissues or cells was homogenized in protein lysis buffer by ultrasonic equipment (KeyGEN, Jiangsu, China) and incubated on ice for 10 min. The processed samples were separated by polyacrylamide gel electrophoresis (PAGE), transferred to Poly (vinylidene fluoride) (PVDF) membranes, and blocked with 3% bovine serum albumin (BSA) for 1 h at room temperature. Subsequently, the membranes were probed with primary antibodies overnight at 4 ℃ and then with HRP-conjugated secondary antibody (1:15000) for 1 h at room temperature. The immunoreactive bands were developed using chemiluminescence reagents (Proteintech, Wuhan, PK10001). Details about the antibodies used are provided in Table S2. Analysis of glucose uptake and lactate production Glucose uptake was measured using a Glucose Uptake Colorimetric Assay Kit (Biovision) according to the manufacturer’s instructions. Bladder cancer cells were seeded in 96-well plates at 1000 cells/well and pre-incubated with 100 µl KRPH buffer containing 2% BSA for 50 min to induce glucose starvation. Cells were stimulated with 1 µM insulin to activate glucose transporters and incubated with 2-DG for 20 min. Absorbance was measured at 412 nm using a microplate reader. Lactate levels were measured using a Lactate Assay Kit II (Sigma-Aldrich) following the manufacturer’s protocols. Metabolic assays (ECAR, PER and OCR) Glycolysis Stress, Glycolytic Rate, and Mito Stress assays were performed using the XF96 Extracellular Flux Analyzer (Agilent, CA, USA). Bladder cancer cells were seeded in 96-well Seahorse XF cell culture microplates at 8.0 × 10³ cells/well with six technical replicates and incubated overnight at 37 °C with 5% CO2. For OCR measurements, the culture medium was replaced with mitochondrial stress assay buffer (Seahorse XF Base Medium supplemented with 10 mM glucose, 2 mM glutamine, and 1 mM pyruvate) 1 h before the assay, and the microplate was incubated in a CO2-free incubator at 37 °C. Oligomycin (1.5 µM), FCCP (0.5 µM), and rotenone/antimycin A (Rot/AA) (0.5 µM) were sequentially injected into the microplate by an XF sensor cartridge. For ECAR measurements, the culture medium was replaced with Glycolysis Stress assay buffer medium (Seahorse XF Base Medium supplemented with 2 mM glutamine) 1 h before the test, and the microplate was incubated in a measuring incubator without CO2 input at 37 °C. Glucose (10 mM), oligomycin (1.0 µM), and 2-deoxy-glucose (2-DG) (50 mM) were sequentially injected into the microplate. For proton efflux rate measurement, the culture medium was replaced with Seahorse XF Glycolytic Rate Assay Medium containing 10 mM glucose, 2 mM glutamine, and 1 mM pyruvate 1 h before the test, and the samples were incubated in a CO2-free incubator at 37 °C. Rot/AA (0.5 µM) and 2-DG (50 mM) were sequentially injected. ECAR and OCR results were analyzed using Seahorse XFe 96 Wave software. After the assay, ECAR/OCR/PER were normalized according to the cell number. Tumor xenograft model Twelve nude mice were randomly assigned to three groups. Each mouse received a subcutaneous injection of 5 × 106 cells, either with or without ALKBH2 knockdown, into the right flank (200µL), to establish xenograft model. The body weights and tumor sizes of the mice were monitored weekly, and their volumes were calculated using the following formula: V (mm³) = 1/2 × length × width². After four weeks, the mice were euthanized, and the tumors were excised, weighed, and subsequently Western blot analysis. Proteomic analysis For each group, three samples were sequenced repeatedly for protein extraction and determination of their concentrations, followed by protein digestion and peptide segment desalination. Before the mass spectrometry sample injection, each sample was mixed at a volume ratio of iRT: sample to be measured = 1:20 by volume, serving as an internal standard. Equal amounts of peptide segments were taken from all the enzymatically digested samples and separated using the EASY-nLC 1200 liquid chromatography. The mobile phase A was 0.1% FA aqueous solution, and the mobile phase B was 0.1% FA ACN. Gradient elution conditions: 0–20 min, 5–22% B; 20 ~ 24 min, 22–37% B; 24 ~ 27 min, 37–80% B; 27–30 min, 80% B. The peptide segments were separated by the ultra-high performance liquid chromatography system and then injected into the timsTOF Pro mass spectrometer (Bruker) for analysis. The mass spectrometry conditions were as follows: capillary voltage 1.4 KV, drying gas temperature 180℃, drying gas flow rate 3.0 L/min, mass spectrometry scanning range 100–1700 m/z, ion drift range 0.7–1.3 Vs/cm2, collision energy range 20–59 eV. The raw data of DIA was processed using Spectronaut Pulsar™ 18.4 (Biognosys, Switzerland) software. The mass spectrometry search parameters were precursor mass value threshold 0.01, protein mass value threshold 0.01, fixed modification as Carbamidomethyl(C), variable modifications as Oxidation(M) and Acetyl(N-term), maximum missed cleavage site 2. The differentially expressed proteins need to meet P < 0.05 and FC > 1.2 or FC < 1/1.2. When P < 0.05 and FC > 1.2, it is a significantly up-regulated protein; when P < 0.05 and FC < 1/1.2, it is a significantly down-regulated protein. The data was imported into the corresponding database for analysis. ALKBH2-associated DNA sequencing To investigate the genomic binding sites of ALKBH2, we performed ALKBH2-associated DNA sequencing. Briefly, UMUC-3, TCCSUP and T24 cells were cross-linked with 1% formaldehyde for 10 min at room temperature to crosslink protein-DNA complexes. Crosslinking was quenched by the addition of glycine to a final concentration of 0.125 M. Cells were then washed with ice-cold PBS containing protease inhibitors and lysed using a sonicator to shear DNA into fragments ranging from 200 to 1000 bp. The resulting lysates were incubated with anti-ALKBH2 antibody (Proteintech) or IgG (Proteintech) overnight at 4 °C with gentle rotation. Antibody-bound complexes were then captured using Protein A/G magnetic beads (Thermo Fisher Scientific, ). Beads were washed extensively, and the DNA was eluted and purified using a DNA purification kit (Thermo Fisher Scientific). DNA libraries were prepared using the NEB. Next Ultra II DNA Library Prep Kit for Illumina (New England Biolabs). Sequencing was performed on an Illumina NovaSeq 6000 platform (Illumina). Reads were aligned to the human genome (hg38) using Bowtie2. Peak calling was performed using MACS2 software with a q-value threshold of 0.05. The resulting peaks were annotated using the R package ChIP seeker with respect to gene features such as promoter, exon, and 3’UTR. Visualization of ALKBH2 binding at the PTEN locus was performed using Integrative Genomics Viewer (IGV). MeRIP-qPCR To determine the m6A modification level of PTEN mRNA, MeRIP-qPCR was performed. Total RNA was extracted from cells using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. Poly(A) mRNA was then isolated using Dynabeads mRNA purification kit (Thermo Fisher Scientific). The mRNA was fragmented into 200 nt fragments using RNA Fragmentation Reagent (Thermo Fisher Scientific). Fragmented RNA was incubated with an anti-m6A antibody (Abcam) or control IgG antibody overnight at 4 °C with rotation. The RNA-antibody complexes were then captured using Protein A/G magnetic beads. The beads were washed and m6A-containing RNA was eluted and purified using TRIzol reagent. The purified RNA was then reverse transcribed into cDNA using PrimeScript RT reagent kit (Takara). qPCR was performed using SYBR Green Master Mix (Applied Biosystems) and specific primers targeting the PTEN mRNA. The primer sequences were: Forward: [ATGACAGCCATCATCAAAGAG]; Reverse: [TCAGACTTTTGTAATTTGTGTATG]. Relative m6A enrichment was calculated by normalizing the m6A-IP signal to the input signal. RNA stability assay To determine the effect of ALKBH2 on PTEN mRNA stability, cells were treated with 5 µg/mL actinomycin D to inhibit transcription. RNA was extracted at 0, 2, 4 and 6 h after actinomycin D treatment. The extracted RNA was reverse transcribed into cDNA. The mRNA levels of PTEN were determined using quantitative real-time PCR (qRT-PCR) with the same primers used in MeRIP-qPCR. The percentage of remaining PTEN mRNA at each time point was calculated relative to the initial level at 0 h. mRNA decay curves were plotted, and statistical significance was determined. Public database and bioinformatic analysis ALKBH2 expression patterns in bladder cancer tissues and corresponding clinical information were obtained from The Cancer Genome Atlas (TCGA) database (http://portal.gdc.cancer.gov). Proteomics analysis made use of GO database (http://www.geneontology.org), KEGG database (https://www.genome.jp/kegg/), Reactome database (https://reactome.org/), Wikipathways database (https://wikipathways.org) and String database (https://string-db.org/). R software V4.0.3 was used for statistical analysis. Statistical analysis SPSS v22.0 software was used for statistical analysis. The data were quantified as the mean ± SD. Oneway analysis of variance (ANOVA) was applied in more than three groups. T-test was used to compare the mean values of the two groups of samples. The rates were analyzed using the Mann-Whitney U test, and p < 0.05 indicated statistical significance. Results ALKBH2 is highly expressed in bladder cancer Although AlkBH3 has been reported to be highly expressed in urological tumors, the expression pattern and clinical relevance of its homolog ALKBH2 remain poorly characterized. Analysis of TCGA datasets revealed that ALKBH2 is upregulated across multiple urological malignancies, with particularly high expression observed in bladder cancer, but the samples are relatively modest (Fig. 1A). Receiver operating characteristic (ROC) curve analysis further demonstrated that ALKBH2 discriminated bladder cancer tissues from normal controls with an area under the curve (AUC) of 0.758, indicating a moderate diagnostic value (Fig. 1B). Fig. 1Expression of ALKBH2 in bladder cancer. (A) Expression of ALKBH2 in different organs based on TCGA data. (B) Diagnostic ROC of AlkKBH2 in bladder cancer. (C) Representative images of bladder cancer and normal para-carcinoma tissue from patients, diagnosed by HE staining (n = 58). Scale bar, 50 μm. (D) Representative immunohistochemical images of ALKBH2 expression in a bladder cancer tissue microarray (n = 58). Scale bar, 50 μm. (E) Western blotting analysis of ALKBH2 expression in bladder cancer tissues and normal tissues (n = 58). (F) Expression analysis of ALKBH2 mRNA and protein between normal and bladder cancer tissues (n = 58). (G) Cox regression analyses evaluated the correlation between ALKBH2 expression. The comparison of ALKBH2 RNA levels is based on the median value selected by the dichotomy method. Data are shown as mean ± SD. *** p < 0.001, ** p < 0.01, * p < 0.05 Expression of ALKBH2 in bladder cancer. (A) Expression of ALKBH2 in different organs based on TCGA data. (B) Diagnostic ROC of AlkKBH2 in bladder cancer. (C) Representative images of bladder cancer and normal para-carcinoma tissue from patients, diagnosed by HE staining (n = 58). Scale bar, 50 μm. (D) Representative immunohistochemical images of ALKBH2 expression in a bladder cancer tissue microarray (n = 58). Scale bar, 50 μm. (E) Western blotting analysis of ALKBH2 expression in bladder cancer tissues and normal tissues (n = 58). (F) Expression analysis of ALKBH2 mRNA and protein between normal and bladder cancer tissues (n = 58). (G) Cox regression analyses evaluated the correlation between ALKBH2 expression. The comparison of ALKBH2 RNA levels is based on the median value selected by the dichotomy method. Data are shown as mean ± SD. *** p < 0.001, ** p < 0.01, * p < 0.05 To validate these findings and make up for the aforementioned shortage of samples, bladder cancer specimens from 58 patients at the Affiliated Hospital of Qinghai University were collected and analyzed. Hematoxylin and eosin (H&E) staining was performed to confirm tumor histopathology (Fig. 1C). Notably, quantitative PCR, Western blotting, and immunofluorescence analyses consistently demonstrated that ALKBH2 expression was significantly elevated in bladder cancer tissues compared with adjacent normal tissues (Fig. 1D–F), in agreement with the TCGA data. However, interestingly, we found that ALKBH2 is also differentially expressed in bladder cancer tissues, not only in atypical cells, but also in fibroblasts, smooth muscle cells, and other cells. This might indicate that the DNA damage repair function of the ALKBH2 nucleic acid demethylase is generalized, and the underlying mechanism requires further exploration. Furthermore, univariate survival analysis revealed that tumor size, tumor number, and ALKBH2 expression were significantly associated with overall survival (OS) in patients with bladder cancer. Multivariate Cox regression analysis identified ALKBH2 expression, along with tumor size and tumor number, as independent prognostic predictors of OS (Fig. 1G). Collectively, these results indicate that elevated ALKBH2 expression is closely associated with unfavorable clinical outcomes in bladder cancer, suggesting a potential role for ALKBH2 in malignant progression and its value as a diagnostic and prognostic biomarker. ALKBH2 promotes bladder cancer cell proliferation, migration and invasion in vivo and vitro To investigate the biological function of ALKBH2 in bladder cancer, ALKBH2 expression was first examined in a panel of bladder cancer cell lines. Stable ALKBH2-overexpressing and knockdown cell lines were generated using lentiviral transduction. Transfection efficiency, as assessed by GFP fluorescence, consistently exceeded 85% (Supplementary Figure S1A, B), and successful overexpression or silencing of ALKBH2 was confirmed by Western blotting (Supplementary Figure S1C, D). Functional validation showed that ALKBH2 overexpression increased the proportion of cells in proliferative phases of the cell cycle, whereas ALKBH2 knockdown resulted in G1-phase arrest (Supplementary Figure S1E, F). Consistently, ALKBH2 overexpression enhanced cell proliferation and suppressed apoptosis, while opposite effects were observed upon ALKBH2 silencing (Supplementary Figure S1G, H). These data confirm the successful establishment of ALKBH2 gain- and loss-of-function models. Using these stable cell lines, we next evaluated the effects of ALKBH2on bladder cancer cell behavior. Cell viability assays revealed that ALKBH2 overexpression significantly promoted cell proliferation, whereas ALKBH2 knockdown markedly reduced cell growth across multiple bladder cancer cell lines (Fig. 2A). Colony formation assays further demonstrated that ALKBH2 overexpression increased clonogenic capacity, while ALKBH2 silencing substantially impaired colony formation (Fig. 2B, C). Wound-healing assays showed that ALKBH2 overexpression significantly enhanced migratory ability, whereas ALKBH2 knockdown inhibited cell migration compared with control cells (Fig. 2D, E). Consistently, Transwell assays confirmed that ALKBH2 overexpression increased both migration and invasion potential, while ALKBH2 knockdown produced the opposite effects (Fig. 2F, G). Fig. 2ALKBH2 promotes bladder cancer cell proliferation, migration, and invasion in vitro. (A) CCK-8 assays analysis of cell number to indicate the proliferation of cells n = 6). (B, C) Colony formation assay to assess cell proliferation in bladder cancer cells, and the number of colonies was quantified in the lower magnification (n = 3). (D, E) Wound healing assay to evaluate the effect of ALKBH2 expression on the migration of cells (n = 3). (F, G) The effects of ALKBH2 knockdown and overexpression on the migration and invasion abilities of cells were evaluated by Transwell assay. Representative images (left panel) and summary bar graphs (right panel) are shown (n = 3). Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05 ALKBH2 promotes bladder cancer cell proliferation, migration, and invasion in vitro. (A) CCK-8 assays analysis of cell number to indicate the proliferation of cells n = 6). (B, C) Colony formation assay to assess cell proliferation in bladder cancer cells, and the number of colonies was quantified in the lower magnification (n = 3). (D, E) Wound healing assay to evaluate the effect of ALKBH2 expression on the migration of cells (n = 3). (F, G) The effects of ALKBH2 knockdown and overexpression on the migration and invasion abilities of cells were evaluated by Transwell assay. Representative images (left panel) and summary bar graphs (right panel) are shown (n = 3). Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05 At the molecular level, ALKBH2 overexpression led to increased expression of proliferation-associated proteins, including MCM2, PCNA, and Cyclin D1, whereas these markers were downregulated in ALKBH2-knockdown cells (Fig. 3A, B). In contrast, tumor suppressor proteins such as p53, p16, and Rb were reduced upon ALKBH2 overexpression but elevated following ALKBH2 silencing (Fig. 3C, D). Moreover, proteins associated with cell migration and invasion were upregulated in ALKBH2-overexpressing cells and downregulated in ALKBH2-knockdown cells (Fig. 3E, F). Together, these in vitro data indicate that ALKBH2 promotes malignant phenotypes in bladder cancer cells. Fig. 3ALKBH2 regulates the expression of proteins associated with cell proliferation, tumor suppression, migration, and invasion. (A) Representative Western blot image of proliferation proteins in bladder cancer cells. (B) Densitometry was used to compare the expression levels. Mean densities of MCM2, PCNA, and Cyclin D1 in the three groups, compared to control (n = 3). (C) Representative Western blot image of cancer suppressor proteins in bladder cancer cells. (D) Mean densities of p53, p16, and Rb in the three groups, compared to control (n = 3). (E) Representative Western blot image of proteins involved in tumor migration and invasion in bladder cancer cells. (F) Mean densities of E-Cadherin, Vimentin, Snail and VEGF in the three groups, compared to control (n = 3). (G) xenograft model was used to assess the effect of ALKBH2 on tumor growth. The photograph of xenografts with control, overexpression and knockdown (n = 12). (H) Volume and weight of xenografts was measured and quantified. V (mm³) = 1/2 × length × width². Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05 ALKBH2 regulates the expression of proteins associated with cell proliferation, tumor suppression, migration, and invasion. (A) Representative Western blot image of proliferation proteins in bladder cancer cells. (B) Densitometry was used to compare the expression levels. Mean densities of MCM2, PCNA, and Cyclin D1 in the three groups, compared to control (n = 3). (C) Representative Western blot image of cancer suppressor proteins in bladder cancer cells. (D) Mean densities of p53, p16, and Rb in the three groups, compared to control (n = 3). (E) Representative Western blot image of proteins involved in tumor migration and invasion in bladder cancer cells. (F) Mean densities of E-Cadherin, Vimentin, Snail and VEGF in the three groups, compared to control (n = 3). (G) xenograft model was used to assess the effect of ALKBH2 on tumor growth. The photograph of xenografts with control, overexpression and knockdown (n = 12). (H) Volume and weight of xenografts was measured and quantified. V (mm³) = 1/2 × length × width². Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05 To further validate these findings in vivo, a subcutaneous xenograft mouse model was established to assess the effect of ALKBH2 on tumor growth (Fig. 3G). Tumors derived from ALKBH2-overexpressing cells exhibited a markedly accelerated growth rate compared with control tumors, whereas tumors formed by ALKBH2-knockdown cells showed significantly suppressed growth. Quantitative analysis revealed that ALKBH2 overexpression increased tumor volume and tumor weight by approximately 61.2% and 60.9%, respectively, whereas ALKBH2 knockdown reduced tumor volume and weight by approximately41.6% and 35.5% compared with controls (Fig. 3H). Collectively, these results demonstrate that ALKBH2 promotes bladder cancer cell proliferation, migration, and invasion both in vitro and in vivo, supporting a critical role for ALKBH2 in bladder cancer progression. Knockdown of ALKBH2 suppresses the Warburg effect in bladder cancer cells The Warburg effect refers to the preferential conversion of glucose to lactate in tumor cells, even in the presence of oxygen [22]. Given the prominent role of metabolic reprogramming in hypoxic tumors, we hypothesized that ALKBH2 might contribute to hypoxia-associated glycolytic remodeling in bladder cancer cells. Consistent with this hypothesis, exposure to hypoxia (1% O₂) markedly altered the proliferative and motile phenotypes of bladder cancer cells. While hypoxia imposed metabolic stress, control cells retained the capacity to sustain growth under hypoxic conditions, whereas ALKBH2 knockdown led to a pronounced reduction in cell growth specifically under hypoxia, indicating that ALKBH2 is required for maintaining cellular fitness in a low-oxygen microenvironment (Fig. 4A). Similarly, hypoxia enhanced the migratory and invasive capacities of bladder cancer cells, while silencing ALKBH2 significantly attenuated these hypoxia-induced effects (Fig. 4B–E). Fig. 4ALKBH2 promotes the Warburg effect in bladder cancer cells. (A) Compared to control, the growth tendency of cells in three groups by CCK-8 (n = 6). (B, C) Transwell to assess migration and invasion abilities, and the number of cells was quantified (n = 3). (D, E) Wound healing assay to evaluate the migration of cells in three groups, compared to control (n = 3). (F) The ability of glucose uptake assay was detected in bladder cancer cells (n = 6). (G) The lactate was observed in bladder cancer cells (n = 6). Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05 ALKBH2 promotes the Warburg effect in bladder cancer cells. (A) Compared to control, the growth tendency of cells in three groups by CCK-8 (n = 6). (B, C) Transwell to assess migration and invasion abilities, and the number of cells was quantified (n = 3). (D, E) Wound healing assay to evaluate the migration of cells in three groups, compared to control (n = 3). (F) The ability of glucose uptake assay was detected in bladder cancer cells (n = 6). (G) The lactate was observed in bladder cancer cells (n = 6). Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05 Fig. 5ALKBH2 promotes the Warburg effect and cell proliferation by activating the PI3K/AKT pathway through m6A-dependent regulation of PTEN. (A-C) UMUC-3, TCCSUP, and T24 bladder cancer cells were treated with DMSO (Control), the PI3K inhibitor LY294002 (20 µM), or LY294002 in combination with ALKBH2 overexpression (LY294002+). (A) Cell proliferation was measured by CCK-8 assay at indicated time points (n = 6). (B) Cellular glucose uptake was assessed using a fluorescent glucose analog (2-NBDG) and measured by flow cytometry (n = 6). (C) Lactate production in the culture medium was quantified using a lactate assay kit (n = 6). (D-E) Protein levels of PI3K and AKT in the three cell lines under the indicated treatments were analyzed by western blotting. (F) ChIP-seq track showing the specific binding enrichment of ALKBH2 at the PTEN gene locus, with prominent peaks in the exon and 3’UTR regions, IgG as the negative control. (G) Relative m6A enrichment on PTEN mRNA was measured by MeRIP-qPCR. Compared to control. (H) PTEN mRNA stability was assessed by qRT-PCR after transcription arrest with Actinomycin D (5 µg/mL). The half-life of PTEN mRNA was calculated (n = 3). Compared to control. Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05 ALKBH2 promotes the Warburg effect and cell proliferation by activating the PI3K/AKT pathway through m6A-dependent regulation of PTEN. (A-C) UMUC-3, TCCSUP, and T24 bladder cancer cells were treated with DMSO (Control), the PI3K inhibitor LY294002 (20 µM), or LY294002 in combination with ALKBH2 overexpression (LY294002+). (A) Cell proliferation was measured by CCK-8 assay at indicated time points (n = 6). (B) Cellular glucose uptake was assessed using a fluorescent glucose analog (2-NBDG) and measured by flow cytometry (n = 6). (C) Lactate production in the culture medium was quantified using a lactate assay kit (n = 6). (D-E) Protein levels of PI3K and AKT in the three cell lines under the indicated treatments were analyzed by western blotting. (F) ChIP-seq track showing the specific binding enrichment of ALKBH2 at the PTEN gene locus, with prominent peaks in the exon and 3’UTR regions, IgG as the negative control. (G) Relative m6A enrichment on PTEN mRNA was measured by MeRIP-qPCR. Compared to control. (H) PTEN mRNA stability was assessed by qRT-PCR after transcription arrest with Actinomycin D (5 µg/mL). The half-life of PTEN mRNA was calculated (n = 3). Compared to control. Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05 To directly evaluate glycolytic remodeling, we quantified glucose utilization and lactate production. Hypoxia increased glucose uptake/consumption and lactate accumulation in control cells, consistent with a shift toward glycolysis. In contrast, ALKBH2 knockdown significantly reduced hypoxia-induced glucose consumption and lactate production, suggesting that ALKBH2 promotes glycolytic flux and lactate generation under hypoxic stress (Fig. 4F, G). We next performed Seahorse extracellular flux analyses to further characterize mitochondrial respiration and glycolytic activity. In the Mito Stress assay, hypoxia markedly reduced basal respiration, maximal respiration, and spare respiratory capacity in control bladder cancer cells, reflecting suppression of mitochondrial oxidative phosphorylation (OXPHOS). Notably, ALKBH2 knockdown significantly restored these OCR parameters toward normoxic levels (Supplementary Figure S2A–D), indicating a metabolic shift away from glycolysis and back toward mitochondrial respiration. These findings suggest that ALKBH2 facilitates a Warburg-like metabolic phenotype under hypoxic conditions by promoting glycolysis while concomitantly repressing mitochondrial oxidative metabolism. Consistent with this interpretation, glycolytic function assessed by the Glycolytic Rate assay revealed that hypoxia enhanced basal glycolysis, increased the proportion of proton efflux derived from glycolysis, and elevated compensatory glycolysis in control cells (Supplementary Figure S2E–H). Similarly, ECAR-based analyses demonstrated that hypoxia amplified glycolysis, glycolytic capacity, and glycolytic reserve (Supplementary Figure S2I–L). In contrast, ALKBH2 knockdown consistently attenuated these hypoxia-induced glycolytic responses, further supporting a role for ALKBH2 in reinforcing hypoxia-driven glycolytic reprogramming. Collectively, these data demonstrate that hypoxia induces a Warburg-like metabolic shift characterized by elevated glucose utilization, increased lactate production, and enhanced glycolytic activity. Silencing ALKBH2 blunts this hypoxia-driven metabolic reprogramming and compromises the ability of bladder cancer cells to maintain malignant phenotypes under low-oxygen conditions, indicating that ALKBH2 is an important facilitator of the Warburg effect in bladder cancer cells. ALKBH2 downregulation inhibits the PI3K/AKT signaling pathway in bladder cancer To elucidate the molecular mechanisms underlying the effects of ALKBH2 on bladder cancer cells, quantitative proteomic analysis was performed. Principal component analysis, and sample correlation analysis demonstrated high consistency and reliability among samples (Supplementary Figure S3A, B). Comprehensive analysis, including visualization of differentially expressed proteins, Venn diagram identification of 23 overlapping proteins (Supplementary Figure S3C, D), subcellular localization mapping (Supplementary Figure S3E), and enrichment and volcano plot assessments (Supplementary Figure S3F-H), revealed distinct expression profiles and cellular distributions associated with ALKBH2 modulation. In addition, enrichment analyses, and volcano plots highlighted distinct expression profiles associated with ALKBH2 modulation. However, the functional classification of the identified proteins revealed that although there was a significant enrichment in biological processes related to protein tyrosine kinase binding and glycolytic metabolism (Supplementary Figure S3I, J), no specific pathways could be directly attributed to them. Nevertheless, glycolytic metabolism is a hallmark of cancer metabolic reprogramming, and we hypothesize that this metabolic reprogramming may be regulated by the PI3K/AKT signaling pathway, consistent with findings by Shahid Karim et al., who reported PI3K/AKT-mediated regulation of glycolysis in colorectal cancer [23]. To validate the assumption results, Western blot analysis was performed, which confirmed that ALKBH2 overexpression increased, whereas ALKBH2 knockdown decreased, the protein levels of PI3K and AKT (Supplementary Figure S4). Furthermore, under hypoxic conditions, phosphorylation of PI3K and AKT was markedly increased, indicating activation of the PI3K/AKT pathway, whereas ALKBH2 knockdown significantly attenuated this hypoxia-induced activation (Supplementary Figure S4A, B). Immunofluorescence analysis further corroborated these findings, showing enhanced PI3K and AKT expression in ALKBH2-overexpressing cells and reduced expression in ALKBH2-knockdown cells (Supplementary Figure S4C–F). ALKBH2 promotes the Warburg effect and cell proliferation by activating the PI3K/AKT pathway through m6A-dependent regulation of PTEN To investigate the role of ALKBH2 in regulating the Warburg effect through the PI3K/AKT pathway. Cell proliferation assays (Fig. 5 A) demonstrated that inhibition of PI3K with LY294002 significantly reduced cell proliferation in all three cell lines compared to the control group. Overexpression of ALKBH2 partially rescued the proliferative defect induced by LY294002, showing significantly higher cell numbers than the LY294002-treated group, although proliferation remained lower than the control. This suggests that ALKBH2 can, at least partially, overcome the growth-inhibitory effects of PI3K inhibition. Functional assays demonstrated that pharmacological inhibition of PI3K with LY294002 significantly suppressed glucose uptake, and lactate production in UMUC-3, TCCSUP, and T24 cells. LY294002 treatment significantly decreased glucose uptake in all cell lines compared to the control. ALKBH2 overexpression partially restored glucose uptake in the presence of inhibitor(Fig. 5B). Lactate production, a key indicator of the Warburg effect, was significantly reduced by LY294002 treatment in all cell lines (Fig. 5C). Overexpression of ALKBH2 partially rescued the lactate production in the presence of LY294002. Notably, these inhibitory effects were markedly rescued by the overexpression of ALKBH2, which concurrently restored the phosphorylation level of PI3K and AKT diminished by LY294002, the same as results of protein level we detected, indicating that ALKBH2 can, to some extent, reverse the inhibitory effect of LY294002 on phosphorylation of PI3K/AKT signaling (Fig. 5D, E). To elucidate the underlying mechanism, we performed ChIP assays, which revealed that ALKBH2 directly binds to the genomic locus of PTEN, specifically enriching at the exon and 3’UTR regions (Fig. 5F). Interestingly, given the structural homology of ALKBH2 to RNA demethylases, we further investigated its impact on RNA modifications. MeRIP-qPCR analysis showed that ALKBH2 overexpression significantly reduced m6A enrichment on PTEN mRNA, compared with control (Fig. 5G). Furthermore, we conducted an in-depth study and found that when compared with the control group, the overexpression of ALKBH2 significantly reduced the stability of PTEN mRNA, while its knockdown produced the opposite effect (Fig. 5H). These data suggest that the overexpression of ALKBH2 significantly reduced the m6A modification on the PTEN mRNA, while its knockdown increased this modification. This indicates that ALKBH2 is a negative regulator of m6A modification in PTEN mRNA, likely achieved through its demethylase activity. However, the relationship between the binding of ALKBH2 to PTEN and the modification of m6A reduction needs to be further explored. Discussion ALKBH2 is a major dioxygenase involved in repairing alkylation damage in genomic DNA, and its dysregulation has been implicated in genome stability maintenance, particularly in repetitive genomic regions such as rDNA [24]. Although ALKBH2 and ALKBH3 share structural similarity and catalytic capacity for removing alkyl adducts [25]. the functional contribution of ALKBH2 to tumor progression has remained largely unexplored. In the present study, we demonstrate that ALKBH2 is aberrantly upregulated in bladder cancer and is associated with aggressive tumor phenotypes and poor clinical outcome. More importantly, we provide the first evidence that ALKBH2 exerts a non-canonical function beyond DNA repair, acting as an RNA m⁶A demethylase to drive metabolic reprogramming and tumor progression. Our data identify a previously unrecognized ALKBH2–PI3K/AKT axis, which operates prominently under hypoxic conditions and promotes the Warburg effect in bladder cancer cells. Hypoxia is a defining feature of solid tumors, including bladder cancer, and represents a major selective pressure rather than a favorable growth condition [26]. Cancer cells exposed to hypoxia must overcome metabolic stress, oxidative imbalance, and genomic instability to maintain survival and proliferative capacity [27]. In this context, our findings show that hypoxia robustly induces ALKBH2 expression. This induction should not be interpreted as a passive response, but rather as an adaptive strategy that enhances cellular fitness under hypoxic stress. By upregulating ALKBH2, bladder cancer cells appear to acquire an increased capacity to tolerate adverse microenvironmental conditions and sustain malignant behaviors, including proliferation, migration, and invasion. Metabolic reprogramming is a critical component of tumor adaptation, and our functional metabolic analyses provide direct evidence that ALKBH2 reshapes cellular energy metabolism. Seahorse assays revealed that ALKBH2 overexpression significantly increased extracellular acidification rate (ECAR), glycolytic capacity, and proton efflux rate, accompanied by enhanced glucose utilization and lactate accumulation, while oxidative phosphorylation was relatively suppressed. Conversely, ALKBH2 knockdown impaired glycolytic flux. This metabolic shift toward aerobic glycolysis supplies not only ATP but also essential biosynthetic intermediates required for nucleotide, protein, and lipid synthesis, thereby supporting rapid tumor cell growth and invasion. Consistent with previous studies demonstrating that glycolysis is elevated in most tumors [28], our data position ALKBH2 as an active driver of the Warburg phenotype rather than a mere downstream consequence of hypoxia. Traditionally, ALKBH2 has been regarded primarily as a DNA repair enzyme that removes alkylation damage from genomic DNA [29]. However, ALKBH2 belongs to the AlkB family of Fe(II)/α-ketoglutarate–dependent dioxygenases, which also includes established RNA m⁶A demethylases such as FTO and ALKBH5 [30]. Increasing evidence indicates that AlkB family members may exert broader regulatory functions beyond DNA repair [30]. In line with this concept, our study reveals a functional paradigm shift for ALKBH2, demonstrating that it also acts as an epitranscriptomic regulator capable of modulating RNA m⁶A modifications. This finding expands the current understanding of ALKBH2 biology and suggests that AlkB family proteins may play more diverse roles in cancer than previously appreciated. Mechanistically, we identified PTEN as a direct RNA target of ALKBH2. ALKBH2-associated DNA pulldown sequencing confirmed that ALKBH2 physically associates with PTEN mRNA, and m⁶A analyses demonstrated that ALKBH2 removes m⁶A modifications from PTEN transcripts. Notably, in this specific context, loss of m⁶A marks resulted in decreased PTEN mRNA stability and accelerated degradation, rather than transcript stabilization. This observation is consistent with the context-dependent nature of m⁶A-mediated RNA regulation and highlights the complexity of epitranscriptomic control. As a consequence, ALKBH2-mediated demethylation led to a marked reduction in PTEN protein levels, thereby weakening a key tumor-suppressive barrier. Given that ALKBH2 has been reported to be a nucleic acid demethylase with activity on both DNA and RNA substrates, we hypothesize that the binding of ALKBH2 to the specific region of the PTEN gene may bring it spatially close to the transcribing PTEN RNA. This positioning is conducive to ALKBH2 contacting and removing the m6A modifications on the newly transcribed PTEN RNA transcripts, thereby linking the DNA binding event with the RNA epigenetic regulation. Subsequently, we will conduct further research by constructing m6A site mutants, combined with RNA stability assays and protein translation detection, to more rigorously elucidate the specific regulatory mechanism of the ALKBH2-m6A-PTEN axis. PTEN is a classical negative regulator of the PI3K/AKT signaling pathway, functioning as a molecular brake on oncogenic signaling [31]. Dysregulation of the PI3K/AKT pathway has been widely implicated in tumorigenesis and metastasis, including bladder cancer [32, 33]. In our study, hypoxia markedly activated PI3K and AKT phosphorylation, whereas silencing ALKBH2 effectively suppressed this signaling cascade. By destabilizing PTEN, ALKBH2 removes inhibitory constraints on phosphorylation of PI3K/AKT signaling, leading to sustained pathway activation. Importantly, pharmacological inhibition of p-PI3K using LY294002 significantly reversed ALKBH2-induced glycolytic reprogramming, proliferation, migration, and invasion. These rescue experiments provide strong causal evidence that ALKBH2 promotes the Warburg effect and malignant progression predominantly through inhibition of the PTEN, and activation of phosphorylation in PI3K/AKT signaling. Several limitations of this study should be acknowledged. Although our data support a non-canonical role of ALKBH2 as an RNA m⁶A demethylase, the structural determinants governing its substrate specificity toward PTEN mRNA require further investigation. In addition, larger clinical cohorts and additional in vivo models will be necessary to fully validate the prognostic value of ALKBH2 in bladder cancer. Finally, whether ALKBH2 regulates additional m⁶A-modified transcripts involved in metabolic adaptation under hypoxia remains an important topic for future research. Conclusion In conclusion, our study uncovers a previously unappreciated ALKBH2-centered regulatory network that links epitranscriptomic control to metabolic reprogramming and oncogenic signaling in bladder cancer. High ALKBH2 expression may serve as a diagnostic and prognostic biomarker, and targeting the ALKBH2/PTEN/PI3K/AKT axis may offer new therapeutic opportunities. Given its dual roles in RNA regulation and metabolic adaptation, ALKBH2 represents a promising target that could potentially synergize with anti-metabolic or anti-hypoxia therapies to improve bladder cancer treatment outcomes. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 : Supplementary Figure 1. ALKBH2 overexpression and knockdown in bladder cancer cell lines. (A, B) The rate of transfection was calculated under the immunofluorescent microscope (n=6). Scale bar, 50μm. (C, D) Western blotting analysis of ALKBH2 expression in bladder cancer cells (n=6). (E, F) Flow cytometry showed the cell cycle, analysis of percentage of different phases of cells (n=3). (G, H) Flow cytometry analysis of apoptosis. Apoptosis rate was quantified (n=3). Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05. Supplementary Material 2 : Supplementary Figure 1. ALKBH2 overexpression and knockdown in bladder cancer cell lines. (A, B) The rate of transfection was calculated under the immunofluorescent microscope (n=6). Scale bar, 50μm. (C, D) Western blotting analysis of ALKBH2 expression in bladder cancer cells (n=6). (E, F) Flow cytometry showed the cell cycle, analysis of percentage of different phases of cells (n=3). (G, H) Flow cytometry analysis of apoptosis. Apoptosis rate was quantified (n=3). Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05. Supplementary Material 3 : Supplementary Figure 2. ALKBH2 regulates the Warburg effect in bladder cancer cells by cell metabolism. (A-D) Mito Stress assays of bladder cancer cells cultured and transfected as in panel. The basal respiration, maximal respiration and reserve respiration of cells were quantified following the OCR (n=3). (E-H) PER was measured to assess the function of glycolysis. Basal glycolysis, percentage of proton efflux rate from glycolysis and compensatory glycolysis were quantified following the PER (n=3). (I-L) The glycolytic function was assessed by ECAR. glycolysis level, maximum glycolytic capacity and glycolytic reserve were quantified following the ECAR (n=3). Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05. Supplementary Material 3 : Supplementary Figure 2. ALKBH2 regulates the Warburg effect in bladder cancer cells by cell metabolism. (A-D) Mito Stress assays of bladder cancer cells cultured and transfected as in panel. The basal respiration, maximal respiration and reserve respiration of cells were quantified following the OCR (n=3). (E-H) PER was measured to assess the function of glycolysis. Basal glycolysis, percentage of proton efflux rate from glycolysis and compensatory glycolysis were quantified following the PER (n=3). (I-L) The glycolytic function was assessed by ECAR. glycolysis level, maximum glycolytic capacity and glycolytic reserve were quantified following the ECAR (n=3). Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05. Supplementary Material 4 : Supplementary Figure 3. Proteomics analysis of ALKBH2-regulated protein expression in bladder cancer cells. (A) Principal Component Analysis (PCA) showing relationships among samples (n=3). (B) Box plot distribution of data fluctuation. (C) Number of significantly upregulated and downregulated proteins in different groups. (D) Venn diagram showing intersecting proteins across groups. (E) Subcellular localization of differential proteins. (F, G) Total proteins of cells. (H-J) Enrichment analysis by different database. Supplementary Material 4 : Supplementary Figure 3. Proteomics analysis of ALKBH2-regulated protein expression in bladder cancer cells. (A) Principal Component Analysis (PCA) showing relationships among samples (n=3). (B) Box plot distribution of data fluctuation. (C) Number of significantly upregulated and downregulated proteins in different groups. (D) Venn diagram showing intersecting proteins across groups. (E) Subcellular localization of differential proteins. (F, G) Total proteins of cells. (H-J) Enrichment analysis by different database. Supplementary Material 5 : Supplementary Figure 4. ALKBH2 regulates the PI3K/AKT signaling pathway in bladder cancer cells. (A) Representative Western blot image of the PI3K/AKT signaling pathway in bladder cancer cells. (B) Mean densities of P-PI3K, PI3K, P-AKT and AKT in the three groups, compared to hypoxia group (n=3). (C, D) Representative immunohistochemical images of PI3K/AKT signaling pathway expression in a bladder cancer microarray. (E) Relative fluorescence intensity of PI3K was quantified in UMUC-3, T24 and TCCSUP, compared to hypoxia group (n=3). (F) Relative fluorescence intensity of AKT was quantified, compared to hypoxia group (n=3). Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05. Supplementary Material 5 : Supplementary Figure 4. ALKBH2 regulates the PI3K/AKT signaling pathway in bladder cancer cells. (A) Representative Western blot image of the PI3K/AKT signaling pathway in bladder cancer cells. (B) Mean densities of P-PI3K, PI3K, P-AKT and AKT in the three groups, compared to hypoxia group (n=3). (C, D) Representative immunohistochemical images of PI3K/AKT signaling pathway expression in a bladder cancer microarray. (E) Relative fluorescence intensity of PI3K was quantified in UMUC-3, T24 and TCCSUP, compared to hypoxia group (n=3). (F) Relative fluorescence intensity of AKT was quantified, compared to hypoxia group (n=3). Data are shown as mean ± SD. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. *** p < 0.001, ** p < 0.01, * p < 0.05.